Pluri launches immunotherapy platform for solid tumour cancer treatment: Haifa, Israel Saturday, May 4, 2024, 17:00 Hrs [IST] Pluri Inc, a leading biotechnology company that trans ...

Poseida is eligible to receive development and sales based milestone payments plus contingency payments up to $550m.

Astellas Pharma Inc. (ALPMY, ALPMY) said that its subsidiary, Xyphos Biosciences Inc, and Poseida Therapeutics Inc. (PSTX) have ...

Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs targeting solid tumors - TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ -- Astellas Pharma Inc.

Astellas is in the market for a new CAR, and Poseida Therapeutics has a shiny convertible just the right size. | Astellas is ...

"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform ...

The more quickly manufacturing and release obstructions can be cleared, the sooner lifesaving treatments can be administered.

Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation (HSCT) has the potential for long-term tumor elimination. However, pre-HSCT ...

William Blair analyst Sami Corwin has maintained their bullish stance on PSTX stock, giving a Buy rating on April 22. Sami Corwin’s ...

an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.

Astellas, Poseida Therapeutics ink research collaboration & license agreement to develop allogeneic cell therapies in oncology: Tokyo Friday, May 3, 2024, 10:00 Hrs [IST] Astellas ...